Fáddáevttohusat
Čájehuvvojit 1 - 20 oktiibuot 54 bohtosis ohcui ', ohcanáigi: 0,03s Aiddostahte ozu
  1. 1
    The emergence of the SARS-CoV-2 Omicron variant

    The emergence of the SARS-CoV-2 Omicron variant

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    How is Omicron different?

    How is Omicron different?

    Almmustuhtton 2022
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Comparison of immune resilience induced by vaccination versus COVID recovery

    Comparison of immune resilience induced by vaccination versus COVID recovery

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals

    mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    SARS-CoV-2 variants implications for immunity and vaccine development /

    SARS-CoV-2 variants implications for immunity and vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Emergence of blood clotting disorders resulting from COVID vaccines inoculations

    Emergence of blood clotting disorders resulting from COVID vaccines inoculations

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    SARS-CoV-2 evolution within and between individuals

    SARS-CoV-2 evolution within and between individuals

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    The COVID-19 outbreak April 2021 update /

    The COVID-19 outbreak April 2021 update /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    The immune system response to the SARS-CoV-2 virus March 2021 update /

    The immune system response to the SARS-CoV-2 virus March 2021 update /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    SARS-CoV-2 vaccine rollout campaigns

    SARS-CoV-2 vaccine rollout campaigns

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    COVID-19 epidemiology and variants new challenges and future of the pandemic /

    COVID-19 epidemiology and variants new challenges and future of the pandemic /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    SARS-CoV-2 mutations phenotypes and implications for vaccine development /

    SARS-CoV-2 mutations phenotypes and implications for vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    The immune system response to the SARS-CoV-2 virus December 2020 update /

    The immune system response to the SARS-CoV-2 virus December 2020 update /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

    The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Imperial College London's saRNA Vaccine - COVAC1

    Imperial College London's saRNA Vaccine - COVAC1

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    The evolutionary origin of SARS-CoV-2

    The evolutionary origin of SARS-CoV-2

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Human challenge trials for vaccines against COVID-19

    Human challenge trials for vaccines against COVID-19

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    The development of SARS-CoV-2 vaccines

    The development of SARS-CoV-2 vaccines

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Nanotechnologies in the fight against coronaviruses

    Nanotechnologies in the fight against coronaviruses

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: